Table 5.

Additional benefits claimed by the manufacturer compared with those considered as addressed by IQWiG and G-BA

	Manufacturera,b			IQWiG/G-BAa,b
	Mortality	Morbidity	HRQoL	Mortality	Morbidity	HRQoL
Abiraterone acetate	+	+	+	+	+
Aliskiren/amlodipine	+	+
Apixaban	±	Embolism: ± DVT: +		±	Embolism: Knee: – Hip: ± DVT: +
Belatacept	±	+	±	±	IQWiG: ± G-BA: +	±
Belimumab		+	+		G-BA: +	G-BA: ±
Boceprevir		+		±	+
Cabazitaxel	+	+	±	+	±
Emtricitabine/rilpivirine/tenofovir disoproxil	±	±	+
Eribulin	+			+
Extract of Cannabis sativa		+	+		G-BA: +	G-BA: ±
Fampridine		+
Fingolimod		+	±		±	±
Ipilimumab	+	±	±	+		±
Linagliptin		±
Microbial collagenase		+
Pirfenidone	±	+	±	±	±	±
Retigabine		±
Rilpivirine		+	±		IQWiG: + G-BA: ±	±
Tafamidis meglumine		+	+	±	+	±
Telaprevir		+	+		+	±
Ticagrelor	+	+		+	+
Vandetanib		+	±
Vemurafenib	+	±	±	+	±	±

DVT deep vein thrombosis

+ Additional benefit confirmed; ± No significant differences observed, no additional benefit; −Less benefit

^aInformation on http://www.g-ba.de/informationen/nutzenbewertung/ in manufacturers’ dossier and G-BA decision

^bIn case of different subgroups within an EBA, the most positive assessment is stated